Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has completed the sale of the controlling interests in its auditory business and drug pump development program to former principals and shareholders of Advanced Bionics.
Subscribe to our email newsletter
The sale coincides with the closing of the amended merger agreement with Advanced Bionics announced on August 9, 2007. As part of a new schedule of consolidated, fixed earnout payments, Boston Scientific has paid former Advanced Bionics shareholders $650 million. A final payment of $500 million will be paid in March 2009. The former Advanced Bionics principals and shareholders have paid Boston Scientific $150 million for the controlling interests in the auditory business and drug pump development program.
Under the amended merger agreement, Boston Scientific obtains sole management control of the Pain Management business, including the emerging indications program. The Pain Management business and emerging indications program will operate as Boston Scientific Neuromodulation and will continue to be headquartered in Valencia, California.
As part of the transactions, the parties have agreed to dismiss currently pending litigation between Boston Scientific and former Advanced Bionics shareholders.